ReviewDrugs2004
Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Insulin detemir versus insulin glargine for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2011Pooled it
- Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study.Cardiovascular diabetology · 2016Trial
- Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.Diabetes care · 2013Trial
- Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.The Indian journal of medical research · 2012Trial
- New drugs and their performance 10 years after approval: a systematic analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus.Reviews in endocrine & metabolic disorders · 2025Review
- Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.ImmunoTargets and therapy · 2025Review
- Co-opting biology to deliver drugs.Biotechnology and bioengineering · 2014Review
- Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.BMC endocrine disorders · 2014Observational
- Synthesis of chiral N-phosphinyl α-imino esters and their application in asymmetric synthesis of α-amino esters by reduction.Beilstein journal of organic chemistry · 2014Article
- Automated solid-phase peptide synthesis to obtain therapeutic peptides.Beilstein journal of organic chemistry · 2014Review
- Insulin detemir for the treatment of obese patients with type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2012Article
- Detemir as a once-daily basal insulin in type 2 diabetes.Clinical pharmacology : advances and applications · 2011Article
- Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management.International journal of clinical practice · 2010Review
- Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.Clinical drug investigation · 2008Review
- Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.MedGenMed : Medscape general medicine · 2007Review
- Review
- Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Insulin detemir in the treatment of type 1 and type 2 diabetes.Vascular health and risk management · 2006Review
- A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.Drugs · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in patients with type 1 or type 2 diabetes mellitus. Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine. Insulin detemir, administered once or twice daily, is at least as effective as NPH insulin in maintaining overall glycaemic control, with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin in patients with type 1 or type 2 diabetes. Insulin detemir also provides the added clinical benefit of no appreciable bodyweight gain in patients with type 1 diabetes and less bodyweight gain than NPH insulin in patients with type 2 diabetes. Insulin detemir is, therefore, a promising new option for basal insulin therapy in patients with type 1 or 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.